Sequenom, Inc.

CARLSBAD, Calif., Dec. 6, 2023 /PRNewswire/ -- Limmi, a company specializing in AI-driven insights for life sciences, today announced the expansion of its Board of Directors with two key appointments. Rob Lozuk, a healthcare executive and CEO of Syantra, a leader and innovator in liquid biopsy cancer and disease detection, along with Todd Lewis, Vice President at Viasat, a global satellite technology company, have been selected to join Limmi's leadership team. Mr. Lozuk has spent the past 23 years successfully scaling and transacting commercially disruptive technologies across the healthcare arena. Prior to joining Syantra, Rob was the Chief Business Officer at Cardea, culminating in a sale to Paragraf and President of Specific Diagnostics, which was sold to biomerieux. As a public company officer, Rob led the global commercial and operating businesses at Sequenom, growing revenue more than 15X over 4 years. Prior to Sequenom, Rob was the P&L leader for ThermoFisher Scientific's Advanced Staining Business. "Having seen the results that Limmi's AI solutions can provide, I'm excited to help steer the company towards even greater successes in improving patient outcomes through innovation," Mr. Lozuk said. Mr. Lewis currently serves as VP & CTO of the Global Fixed Broadband business at Viasat, a global leader in satellite communications services. Mr. Lewis has spent his career focused on innovative and emerging technologies, including executive positions at Wildblue Communications and OnCommand Corporation. "As Limmi enters a phase of accelerated growth, the insights and experience that Rob and Todd bring to our board are invaluable," said Trevor Vieweg, Chairman of Limmi. "Their arrival is perfectly timed to help us capitalize on the market opportunities ahead." Limmi expects that the unique blend of skills and experiences the new board members bring will provide valuable insights and direction, supporting the company's growth and innovation in the application of AI to healthcare operations and early disease detection. SOURCE Limmi

[01-November-2023] CALGARY, AB, Nov. 1, 2023 /PRNewswire/ - Today, Syantra, a liquid biopsy platform and innovation company that is changing the way cancer is detected, starting with Syantra DXTM Breast Cancer, announced that Rob Lozuk has been appointed as Chief Executive Officer, effective November 1, 2023. "Rob brings over 23 years of experience successfully scaling and transacting commercially disruptive technologies across the healthcare landscape," said Kristina Rinker, PhD, Chief Scientific Officer and Co-founder of Syantra. "We are thrilled to add an accomplished world-class executive to our leadership team to elevate our pivotal work in blood-based cancer detection. Rob will bring substantial value to our organization as we expand into the United States with commercial introduction of the Syantra DXTM Breast Cancer test, a blood test that identifies individuals who may have breast cancer, including early-stage disease." "The existing early cancer detection liquid biopsy paradigm is not adequate, economical, or scalable. Entirely too many early-stage cancers are still being missed, at a time when the opportunity for intervention and survival is the greatest. Truly disruptive healthcare technologies are generational – and that's exactly what Syantra's liquid biopsy platform will become" states CEO of Syantra, Rob Lozuk, and adds, "I'm thrilled to be joining the Syantra team at this critical juncture in the liquid biopsy arena. Our AI powered RNA-based liquid biopsy platform represents a revolution for the screening and detection modalities by measuring a key shift in the body's immune response that allows cancer to develop. We will rapidly expand the clinical data of the Syantra DXTM Breast Cancer blood test over the remainder of 2023 in preparation for broad global commercialization in 2024." Within the precision biotech space, Syantra's liquid biopsy platform has already demonstrated impressive performance statistics as exemplified in the Analytical and Clinical Performance from the Early Analysis of the International Identify Breast Cancer (IDBC) Study, presented by Professor Nigel Bundred, Surgical Oncologist with the Manchester University NHS Foundation Trust, Wythenshawe Hospital, at the 13th European Breast Cancer Conference in Barcelona, Spain, in November of 2022. About Rob Lozuk Prior to joining Syantra, Rob was the Chief Business Officer at Cardea Bio, which culminated in a sale to Paragraf in 2023. Rob was also the President of Specific Diagnostics, which was sold to biomerieux in 2022. As a public company officer, Rob led the global commercial and operating businesses at Sequenom, a pioneer in revolutionizing the prenatal space, which was successfully transacted to Lab Corp (LH). Prior to Sequenom, Rob was the P&L leader for ThermoFisher Scientific's Advanced Staining Business and served as Director of Sales, Marketing and Business Development. About Syantra, Inc. Syantra is a precision biotechnology company changing the way cancer is detected and treated with revolutionary high-performance blood-based tests providing a new way to help detect cancer. Syantra's scalable, patent-protected platform is based on changes in the immune system and other systemic factors that occur when a cancer tumor is present. These changes can be measured through mRNA biomarkers that are contained in a small amount (2.5ml) of blood. When biomarker expression is combined with patient characteristics, there is a high correlation to the presence or absence of disease. The Syantra platform includes a custom real-time PCR process with proprietary software that includes machine learning based algorithms. Syantra's blood testing platform provides a cost-effective way to help identify individuals who may have cancer and should be further evaluated. About the Syantra DXTM Breast Cancer test Syantra is changing the way cancer is detected and treated. Its flagship product, Syantra DXTM Breast Cancer, is a minimally invasive and high-performance blood test for the detection of breast cancer signals at the earliest stages, when breast cancer is easier to treat. The Syantra DXTM Breast Cancer test will be available to women in Canada and the United States in early 2024. For more information about Syantra, the Syantra DX Platform Technology, and the Syantra DXTM Breast Cancer test, please visit: Social Media: LinkedIn, Twitter, Facebook, Instagram

DUBLIN, Sept. 5, 2023 /PRNewswire/ -- The "Protein Chip Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 - By Product, Technology, Grade, Application, End-user and Region (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)" report has been added to ResearchAndMarkets.com's offering. The global protein chip market is undergoing rapid growth, primarily driven by the increasing prevalence of chronic diseases and the escalating demand for advanced treatment options. The evolution of the healthcare sector has played a pivotal role in fueling the market's expansion, owing to the growing necessity for enhanced disease monitoring and clinical diagnostics. A distinctive feature that has contributed significantly to the market's growth is the protein microarray method, which enables a wide range of analyses within a single experiment. Preliminary findings from Fairfield Market Research suggest that the high global incidence of cancer is expected to be a significant driving factor for the protein chip market. Impact of COVID-19 and Cancer Prevalence on the Protein Chip Market: The outbreak of COVID-19 has underscored the critical role of diagnostics in containing the pandemic. Consequently, there has been a surge in demand for functional analysis methods. As researchers focus on identifying protein-virus interactions through various testing methods, functional analysis has emerged as a lucrative growth area. Cancer, a leading cause of reduced life expectancy globally, remains a significant health challenge. The World Health Organization (WHO) reported over 19 million new cancer cases and approximately 10 million cancer-related deaths in 2020. Protein chips play a crucial role in efficient cancer diagnosis by enabling fast and straightforward diagnostics through parallel tracking of diverse protein interactions, targets, small molecules, protein kinases' substrates, and protein-phospholipid interactions. This is expected to drive substantial demand for protein chips. The broad application spectrum of protein chips in molecular biology and biochemistry, coupled with the growth of personalized medicine, further amplifies their significance in the healthcare industry. Proteomics as a Leading Application: Proteomics emerged as the leading application for protein chips in 2019 and is expected to maintain this position in the foreseeable future. Its extensive usage in biomedical research and drug discovery is anticipated to be a major revenue contributor to the market. Proteomics is integral to various techniques, including chromatography, x-ray crystallography, protein fractionation, spectroscopy, surface plasmon resonance, and electrophoresis. Its ability to offer precise analysis of in-vivo outcomes positions it as a crucial tool for studying tumour resistance mechanisms, disease pathogenesis, and therapeutic advancements. Regional Outlook: North America and Europe Taking the Lead: From 2021 to 2026, North America is projected to maintain its dominance in the global protein chip market. Established biotech companies in the region are anticipated to make significant investments in innovative technology research and development. Europe is also poised for positive growth, driven by the rising incidence of cancer and the ongoing impact of COVID-19, prompting swift responses. Asia Pacific is expected to closely follow this trajectory, with the adoption of protein chips for diagnostics presenting promising opportunities. Key Players in the Market: The competitive landscape of the global protein chip market is shaped by key players such as Sigma Aldrich Corporation, Affymetrix, Inc., Biacore, SEQUENOM, Inc., Illumina, Inc., Agilent Technologies, HTS Biosystems, EMD Millipore, Life Technologies Corporation, Lumicyte, and Ciphergen Biosystems. These companies contribute significantly to the advancements and innovations driving the protein chip market's growth. For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets